文献速递认知障碍与痴呆

大型临床队列中阿尔茨海默病血液生物标志物预测痴呆风险的有效性与性能

Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
PubMed 文献 · Neurology · 2022-10-19

在法国26家记忆门诊的MEMENTO前瞻性多中心未选择队列中,2,277例主观认知主诉或轻度认知障碍患者基线血p181-tau单独预测5年阿尔茨海默病/混合性痴呆风险的c-index为0.73;加入临床模型后c-index由0.88升至0.90。血液标志物可反映潜在病理,但对含传统预测因素的5年痴呆风险预测模型增益有限。

要点

  • 血p181-tau是识别淀粉样蛋白PET阳性的最佳血液标志物,AUC为0.74(95%CI 0.69;0.79)。
  • 血p181-tau单独预测5年AD/混合性痴呆风险c-index为0.73,CDR=0者0.83,CDR=0.5者0.70。
  • 临床模型加入血p181-tau+Aβ42/40后c-index由0.88升至0.90,增益有限。

核心结论

  • 在主观认知主诉或轻度认知障碍门诊患者中,血液生物标志物可能是潜在病理的良好标志,但对包含传统预测因素的5年痴呆风险预测模型增益有限。

研究设计与样本

  • MEMENTO为多中心未选择前瞻性队列,纳入法国26家记忆门诊的2,323例主观认知主诉或轻度认知障碍门诊患者。
  • 基线进行神经心理学评估、MRI和采血,脑脊液采样与淀粉样蛋白PET为可选。
  • 基线血液Aβ42/40比值、总tau、p181-tau和神经丝轻链(NfL)采用Simoa HD-X分析仪检测,专家委员会在5年随访期间裁定新发痴呆病例。

主要发现

  • 2,277例至少具备1项基线血液生物标志物(脑脊液子样本n=357,PET子样本n=649),随访期间257例诊断为临床AD/混合性痴呆。
  • 除总tau外,所有血液标志物与脑脊液等效标志物呈轻度相关(r=0.33至0.46,p<0.0001),并与淀粉样蛋白PET状态相关(p<0.0001)。
  • 血p181-tau是识别淀粉样蛋白PET阳性的最佳血液标志物(AUC=0.74[95%CI=0.69;0.79])。
  • 血和脑脊液p181-tau及NfL浓度较高与AD痴呆发病时间加速相关且发病率相似,而血Aβ42/40效率低于脑脊液Aβ42/40。
  • 血p181-tau单独是5年AD/混合性痴呆风险的最佳血液预测指标(c-index=0.73[95%CI=0.69;0.77]),CDR=0者准确性(c-index=0.83[95%CI=0.69;0.97])高于CDR=0.5者(c-index=0.70[95%CI=0.66;0.74])。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Blood biomarkers for Alzheimer disease (AD) have consistently proven to be associated with CSF or PET biomarkers and effectively discriminate AD from other neurodegenerative diseases. Our aim was to test their utility in clinical practice, from a multicentric unselected prospective cohort where patients presented with a large spectrum of cognitive deficits or complaints. METHODS: The MEMENTO cohort enrolled 2,323 outpatients with subjective cognitive complaint (SCC) or mild cognitive impairment (MCI) consulting in 26 French memory clinics. Participants had neuropsychological assessments, MRI, and blood sampling at baseline. CSF sampling and amyloid PET were optional. Baseline blood Aβ42/40 ratio, total tau, p181-tau, and neurofilament light chain (NfL) were measured using a Simoa HD-X analyzer. An expert committee validated incident dementia cases during a 5-year follow-up period. RESULTS: Overall, 2,277 individuals had at least 1 baseline blood biomarker available (n = 357 for CSF subsample, n = 649 for PET subsample), among whom 257 were diagnosed with clinical AD/mixed dementia during follow-up. All blood biomarkers but total tau were mildly correlated with their equivalence in the CSF (r = 0.33 to 0.46, p < 0.0001) and were associated with amyloid-PET status (p < 0.0001). Blood p181-tau was the best blood biomarker to identify amyloid-PET positivity (area under the curve = 0.74 [95% CI = 0.69; 0.79]). Higher blood and CSF p181-tau and NfL concentrations were associated with accelerated time to AD dementia onset with similar incidence rates, whereas blood Aβ42/40 was less efficient than CSF Aβ42/40. Blood p181-tau alone was the best blood predictor of 5-year AD/mixed dementia risk (c-index = 0.73 [95% CI = 0.69; 0.77]); its accuracy was higher in patients with clinical dementia rating (CDR) = 0 (c-index = 0.83 [95% CI = 0.69; 0.97]) than in patients with CDR = 0.5 (c-index = 0.70 [95% CI = 0.66; 0.74]). A "clinical" reference model (combining demographics and neuropsychological assessment) predicted AD/mixed dementia risk with a c-index = 0.88 [95% CI = 0.86-0.91] and performance increased to 0.90 [95% CI = 0.88; 0.92] when adding blood p181-tau + Aβ42/40. A "research" reference model (clinical model + apolipoprotein E genotype and AD signature on MRI) had a c-index = 0.91 [95% CI = 0.89-0.93] increasing to 0.92 [95% CI = 0.90; 0.93] when adding blood p181-tau + Aβ42/40. Chronic kidney disease and vascular comorbidities did not affect predictive performances. DISCUSSION: In a clinic-based cohort of patients with SCC or MCI, blood biomarkers may be good hallmarks of underlying pathology but add little to 5-year dementia risk prediction models including traditional predictors.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Planche V, Bouteloup V, Pellegrin I, et al. Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort. Neurology. 2022. PMID: 36261295. doi:10.1212/WNL.0000000000201479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。